PLA2G4F

Summary

PLA2G4F (phospholipase A2 group IVF, HGNC:27396) is a protein-coding gene on chromosome 15q15.1, encoding Cytosolic phospholipase A2 zeta (Q68DD2). Has calcium-dependent phospholipase and lysophospholipase activities with a potential role in membrane lipid remodeling and biosynthesis of lipid mediators.

Predicted to enable calcium ion binding activity; calcium-dependent phospholipase A2 activity; and calcium-dependent phospholipid binding activity. Predicted to be involved in glycerophospholipid catabolic process. Predicted to act upstream of or within arachidonate secretion; cellular response to antibiotic; and prostaglandin biosynthetic process. Predicted to be located in mitochondrion and plasma membrane. Predicted to be active in cytosol; ruffle membrane; and vesicle.

Source: NCBI Gene 255189 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 202 total
• MANE Select transcript: NM_213600

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27396
Approved symbol	PLA2G4F
Name	phospholipase A2 group IVF
Location	15q15.1
Locus type	gene with protein product
Status	Approved
Aliases	PLA2G4F/Z
Ensembl gene	ENSG00000168907
Ensembl biotype	protein_coding
Entrez	255189

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 9 protein_coding, 5 nonsense_mediated_decay, 1 retained_intron

ENST00000290497, ENST00000397272, ENST00000561627, ENST00000561893, ENST00000562320, ENST00000565553, ENST00000569985, ENST00000888451, ENST00000888452, ENST00000888453, ENST00000888454, ENST00000888455, ENST00000956233, ENST00000956234, ENST00000956235

RefSeq mRNA: 1 — MANE Select: NM_213600 NM_213600

CCDS: CCDS32204

Canonical transcript exons

ENST00000397272 — 20 exons

Exon	Start	End
ENSE00001272519	42139034	42142204
ENSE00001527977	42147626	42147762
ENSE00001679270	42155517	42155589
ENSE00002628508	42156439	42156636
ENSE00003458702	42150373	42150486
ENSE00003461638	42153300	42153342
ENSE00003462239	42144450	42144644
ENSE00003479153	42154092	42154220
ENSE00003502628	42154322	42154458
ENSE00003527719	42142528	42142714
ENSE00003534389	42152688	42152754
ENSE00003536286	42147124	42147346
ENSE00003590606	42150104	42150141
ENSE00003601904	42149713	42149848
ENSE00003619802	42143978	42144144
ENSE00003624495	42153620	42153660
ENSE00003624752	42145766	42145903
ENSE00003645669	42145575	42145682
ENSE00003669112	42146127	42146241
ENSE00003685703	42150608	42150777

Expression profiles

Bgee: expression breadth ubiquitous, 146 present calls, max score 96.95.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4214 / max 378.7413, expressed in 255 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
149544	1.4214	255

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	96.95	gold quality
skin of leg	UBERON:0001511	96.25	gold quality
upper arm skin	UBERON:0004263	95.25	silver quality
zone of skin	UBERON:0000014	93.47	gold quality
nasal cavity epithelium	UBERON:0005384	86.59	gold quality
kidney epithelium	UBERON:0004819	86.22	gold quality
pancreatic ductal cell	CL:0002079	85.10	silver quality
epithelial cell of pancreas	CL:0000083	84.78	gold quality
lower esophagus mucosa	UBERON:0035834	84.19	gold quality
esophagus mucosa	UBERON:0002469	83.38	gold quality
metanephros cortex	UBERON:0010533	83.25	gold quality
mucosa of transverse colon	UBERON:0004991	83.20	gold quality
right lung	UBERON:0002167	82.91	gold quality
heart right ventricle	UBERON:0002080	82.53	gold quality
upper lobe of left lung	UBERON:0008952	82.26	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	82.10	gold quality
left ventricle myocardium	UBERON:0006566	80.71	gold quality
adult mammalian kidney	UBERON:0000082	80.67	gold quality
myocardium	UBERON:0002349	80.67	gold quality
upper lobe of lung	UBERON:0008948	80.42	gold quality
tibialis anterior	UBERON:0001385	80.37	silver quality
hindlimb stylopod muscle	UBERON:0004252	79.92	gold quality
skeletal muscle tissue	UBERON:0001134	79.90	gold quality
ileal mucosa	UBERON:0000331	79.84	gold quality
quadriceps femoris	UBERON:0001377	79.66	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	79.53	gold quality
vastus lateralis	UBERON:0001379	79.52	gold quality
rectum	UBERON:0001052	78.80	gold quality
gastrocnemius	UBERON:0001388	78.76	gold quality
transverse colon	UBERON:0001157	78.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	20.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting PLA2G4F, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-210-5P	98.57	64.37	832
HSA-MIR-1237-3P	98.55	67.65	1423
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-4646-5P	97.70	66.84	1692
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-4797-3P	97.48	67.14	989

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pla2g4f	ENSMUSG00000046971
rattus_norvegicus	Pla2g4f	ENSRNOG00000008135

Paralogs (5): PLA2G4C (ENSG00000105499), PLA2G4A (ENSG00000116711), PLA2G4D (ENSG00000159337), PLA2G4E (ENSG00000188089), PLA2G4B (ENSG00000243708)

Protein

Protein identifiers

Cytosolic phospholipase A2 zeta — Q68DD2 (reviewed: Q68DD2)

Alternative names: Phospholipase A2 group IVF

All UniProt accessions (6): Q68DD2, H3BMD0, H3BNW4, H3BPX7, H3BSG9, H7BXJ8

UniProt curated annotations — full annotation on UniProt →

Function. Has calcium-dependent phospholipase and lysophospholipase activities with a potential role in membrane lipid remodeling and biosynthesis of lipid mediators. Preferentially hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity). Selectively hydrolyzes sn-2 arachidonoyl group from membrane phospholipids, providing the precursor for eicosanoid biosynthesis. In myocardial mitochondria, plays a major role in arachidonate release that is metabolically channeled to the formation of cardioprotective eicosanoids, epoxyeicosatrienoates (EETs).

Subcellular location. Cytoplasm. Cytosol. Cell membrane. Mitochondrion.

Tissue specificity. Expressed in myocardium (at protein level).

Activity regulation. Stimulated by cytosolic Ca(2+).

Domain organisation. The N-terminal C2 domain associates with lipid membranes upon calcium binding. It modulates enzyme activity by presenting the active site to its substrate in response to elevations of cytosolic Ca(2+).

Isoforms (3)

UniProt ID	Names	Canonical?
Q68DD2-1	1	yes
Q68DD2-2	2
Q68DD2-3	3

RefSeq proteins (1): NP_998765* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR002642	LysoPLipase_cat_dom	Domain
IPR016035	Acyl_Trfase/lysoPLipase	Homologous_superfamily
IPR035892	C2_domain_sf	Homologous_superfamily
IPR040723	cPLA2_C2	Domain
IPR041847	C2_cPLA2	Domain

Pfam: PF00168, PF01735, PF18695

Catalyzed reactions (Rhea), 10 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:15801)
• a 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine + H2O = a 1-O-alkyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:36231)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O = 2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + hexadecanoate + H(+) (RHEA:38783)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:40427)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:40431)
• 1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = sn-glycerol 3-phosphocholine + hexadecanoate + H(+) (RHEA:40435)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:40811)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (9Z,12Z)-octadecadienoate + H(+) (RHEA:40815)
• 1-O-hexadecyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine + H2O = 1-O-hexadecyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:41067)
• 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-O-hexadecyl-sn-glycero-3-phosphocholine + H2O = 2-O-hexadecyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:41271)

UniProt features (21 total): binding site 8, splice variant 3, sequence conflict 3, domain 2, sequence variant 2, active site 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68DD2-F1	83.07	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 395 (nucleophile); 680 (proton acceptor)

Ligand- & substrate-binding residues (8): 118; 118; 123; 60; 60; 66; 116; 116

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1482788	Acyl chain remodelling of PC
R-HSA-1482801	Acyl chain remodelling of PS
R-HSA-1482839	Acyl chain remodelling of PE
R-HSA-1482922	Acyl chain remodelling of PI
R-HSA-1482925	Acyl chain remodelling of PG
R-HSA-1483115	Hydrolysis of LPC

MSigDB gene sets: 138 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, PEREZ_TP63_TARGETS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOCC_RUFFLE, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GGGTGGRR_PAX4_03, GOBP_PHOSPHATIDYLGLYCEROL_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SECRETION

GO Biological Process (10): prostaglandin biosynthetic process (GO:0001516), phosphatidylglycerol acyl-chain remodeling (GO:0036148), glycerophospholipid catabolic process (GO:0046475), arachidonate secretion (GO:0050482), cellular response to antibiotic (GO:0071236), lipid metabolic process (GO:0006629), glycerophospholipid metabolic process (GO:0006650), phospholipid catabolic process (GO:0009395), fatty acid transport (GO:0015908), lipid catabolic process (GO:0016042)

GO Molecular Function (10): phosphatidylcholine lysophospholipase A1 activity (GO:0004622), calcium ion binding (GO:0005509), calcium-dependent phospholipid binding (GO:0005544), glycerophospholipid phospholipase A1 activity (GO:0008970), obsolete calcium-dependent phospholipase A2 activity (GO:0047498), glycerophospholipase activity (GO:0004620), A2-type glycerophospholipase activity (GO:0004623), hydrolase activity (GO:0016787), metal ion binding (GO:0046872), carboxylic ester hydrolase activity (GO:0052689)

GO Cellular Component (7): mitochondrion (GO:0005739), cytosol (GO:0005829), vesicle (GO:0031982), ruffle membrane (GO:0032587), cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	6

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
phospholipid metabolic process	2
cytoplasm	2
prostaglandin metabolic process	1
prostanoid biosynthetic process	1
phosphatidylglycerol metabolic process	1
glycerophospholipid metabolic process	1
phospholipid catabolic process	1
glycerolipid catabolic process	1
icosanoid secretion	1
arachidonate transport	1
response to antibiotic	1
cellular response to chemical stimulus	1
primary metabolic process	1
glycerolipid metabolic process	1
lipid catabolic process	1
organophosphate catabolic process	1
lipid transport	1
monocarboxylic acid transport	1
lipid metabolic process	1
catabolic process	1
lysophospholipase A1 activity	1
metal ion binding	1
phospholipid binding	1
A1-type glycerophospholipase activity	1
phospholipase activity	1
glycerophospholipase activity	1
carboxylic ester hydrolase activity	1
catalytic activity	1
cation binding	1
hydrolase activity, acting on ester bonds	1
intracellular membrane-bounded organelle	1
membrane-bounded organelle	1
ruffle	1
cell projection membrane	1
leading edge membrane	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

676 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLA2G4F	PNPLA8	Q9NP80	481
PLA2G4F	PLA2G2A	P14555	460
PLA2G4F	PLA2G3	Q9NZ20	458
PLA2G4F	PLA2G2F	Q9BZM2	434
PLA2G4F	PLA2G2E	Q9NZK7	433
PLA2G4F	TVP23A	A6NH52	429
PLA2G4F	PLA2G6	O60733	404
PLA2G4F	NRN1L	Q496H8	398
PLA2G4F	PNPLA7	Q6ZV29	370
PLA2G4F	PLA2G2D	Q9UNK4	366
PLA2G4F	PLA2G15	Q8NCC3	364
PLA2G4F	PNPLA6	Q8IY17	364
PLA2G4F	EPHX4	Q8IUS5	360
PLA2G4F	RPRML	Q8N4K4	355
PLA2G4F	EFTUD2	Q15029	352

IntAct

10 interactions, top by confidence:

A	B	Type	Score
PLA2G4F	H1-2	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	H1-5	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	H2BC12L	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	H1-1	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	CFAP97	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	H3-4	psi-mi:“MI:0915”(physical association)	0.400
PLA2G4F	HIST2H2BF	psi-mi:“MI:0915”(physical association)	0.400
ALB	SH3BP5	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): PLA2G4F (Proximity Label-MS), PLA2G4F (Proximity Label-MS), PLA2G4F (Proximity Label-MS), HIST1H2BH (Proximity Label-MS), CFAP97 (Proximity Label-MS), PLA2G4F (Proximity Label-MS), PLA2G4F (Proximity Label-MS), PLA2G4F (Proximity Label-MS), PLA2G4F (Negative Genetic), PLA2G4F (Affinity Capture-MS)

ESM2 similar proteins: A0A8C2MDK8, A0PJX2, A2ACG1, D3ZBP4, E2RDP2, F1MH07, O08644, O75038, O75064, O75636, P0C0K7, P0DPD7, P0DPE0, P0DPE1, P52824, Q00653, Q0IID2, Q1LWV7, Q3SYT1, Q3U1Y4, Q4KM32, Q4R380, Q5NCQ5, Q5RKI3, Q62137, Q684M2, Q68DD2, Q6ZSI9, Q86TL0, Q86XP0, Q8BGV9, Q8BX80, Q8C9V1, Q8NFF5, Q8NFI3, Q8R5G7, Q8TDZ2, Q8VDP3, Q8WWN8, Q91ZJ0

Diamond homologs: A0JJX5, A4IFJ5, B1WAZ6, O77793, P47712, P47713, P49147, P50392, P50393, Q08108, Q3MJ16, Q50L41, Q50L42, Q50L43, Q5R8A5, Q60EW9, Q68DD2, Q7T0T9, Q7XA06, Q8L706, Q8RXU9, Q9LEX1, Q9M2D4, Q9TT38, B6ETT4, P0C871, P34693, P53541, Q06846, Q15111, Q3USB7, Q62688, Q8K394, Q9FL59, Q9Y2J0, A0FGR9, Q69ZN7, Q9NZM1, Q9SKR2, C9J798

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

202 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	175
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4272 predictions. Top by Δscore:

Variant	Effect	Δscore
15:42142202:CAC:C	acceptor_gain	1.0000
15:42142206:T:A	acceptor_loss	1.0000
15:42142211:G:GC	acceptor_gain	1.0000
15:42143973:CTCA:C	donor_loss	1.0000
15:42143974:TCAC:T	donor_loss	1.0000
15:42143975:CACCT:C	donor_loss	1.0000
15:42143976:A:AG	donor_loss	1.0000
15:42143977:C:CT	donor_loss	1.0000
15:42143991:T:TA	donor_gain	1.0000
15:42144155:CCCA:C	acceptor_gain	1.0000
15:42144156:CCA:C	acceptor_gain	1.0000
15:42144157:CA:C	acceptor_gain	1.0000
15:42144468:C:CA	donor_gain	1.0000
15:42145571:TCAC:T	donor_loss	1.0000
15:42145572:CACCT:C	donor_loss	1.0000
15:42145573:A:AG	donor_loss	1.0000
15:42145678:CATAC:C	acceptor_gain	1.0000
15:42145680:TAC:T	acceptor_gain	1.0000
15:42145680:TACC:T	acceptor_loss	1.0000
15:42145684:T:C	acceptor_loss	1.0000
15:42145761:CTCA:C	donor_loss	1.0000
15:42145762:TCACC:T	donor_loss	1.0000
15:42145763:CACC:C	donor_loss	1.0000
15:42145764:A:AC	donor_gain	1.0000
15:42145764:A:T	donor_loss	1.0000
15:42145764:AC:A	donor_gain	1.0000
15:42145765:C:CT	donor_gain	1.0000
15:42145765:CC:C	donor_gain	1.0000
15:42145765:CCTTG:C	donor_gain	1.0000
15:42145899:CCACT:C	acceptor_gain	1.0000

AlphaMissense

5506 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:42154363:A:G	W94R	0.987
15:42154363:A:T	W94R	0.987
15:42145901:A:G	W513R	0.982
15:42145901:A:T	W513R	0.982
15:42154361:C:A	W94C	0.981
15:42154361:C:G	W94C	0.981
15:42144029:T:A	R697S	0.977
15:42144029:T:G	R697S	0.977
15:42142547:G:C	F770L	0.976
15:42142547:G:T	F770L	0.976
15:42142549:A:G	F770L	0.976
15:42149779:C:A	R331S	0.974
15:42149779:C:G	R331S	0.974
15:42142667:G:C	F730L	0.973
15:42142667:G:T	F730L	0.973
15:42142669:A:G	F730L	0.973
15:42147315:A:G	W410R	0.973
15:42147315:A:T	W410R	0.973
15:42149791:A:C	F327L	0.970
15:42149791:A:T	F327L	0.970
15:42149793:A:G	F327L	0.970
15:42145677:A:G	W560R	0.968
15:42145677:A:T	W560R	0.968
15:42144463:G:C	F654L	0.966
15:42144463:G:T	F654L	0.966
15:42144465:A:G	F654L	0.966
15:42147697:G:C	S375R	0.966
15:42147697:G:T	S375R	0.966
15:42147699:T:G	S375R	0.966
15:42149780:C:A	R331M	0.965

dbSNP variants (sampled 300 via entrez): RS1000052057 (15:42146973 A>G), RS1000073465 (15:42153902 A>C), RS1000176675 (15:42149968 C>A,G,T), RS1000306170 (15:42145171 G>A), RS1000454589 (15:42154927 A>C,G), RS1000711407 (15:42149418 G>T), RS1000767890 (15:42140381 G>A), RS1000863848 (15:42145345 C>G), RS1000908538 (15:42153780 G>A,C,T), RS1001283745 (15:42156987 C>T), RS1001730654 (15:42156025 G>A,T), RS1001864171 (15:42144288 TGCCTTCCA>T), RS1002010492 (15:42157580 C>T), RS1002028168 (15:42139001 G>A), RS1002076828 (15:42156230 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phospholipase A₂

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
ethyl-p-hydroxybenzoate	increases expression	1
sodium arsenite	affects expression	1
eprenetapopt	affects expression, affects reaction	1
Zoledronic Acid	decreases expression	1
Fulvestrant	increases methylation	1
Leflunomide	increases expression	1
Arsenic	decreases expression, increases abundance	1
Tobacco Smoke Pollution	affects expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Lactic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.